ASHP Midyear Clinical Meeting and Exhibition - American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition

Intradepartmental hospital pharmacy groups can play a key role in helping to identify and troubleshoot problem areas.

Collaboration between physicians, patients, and pharmacists is essential to address the public health crisis of opioid misuse and overdose in the United States.

Intradepartmental hospital pharmacy groups can play a key role in helping to identify and troubleshoot problem areas, according to a presentation at the ASHP Midyear 2016 Clinical Meeting and Exhibition.

Collaboration between physicians, patients, and pharmacists is essential for addressing the public health crisis of opioid misuse and overdose in the United States, according to a presentation at the ASHP Midyear 2016 Clinical Meeting and Exhibition.

Christopher M. Jones, PharmD, CDR, US Public Health Service, discusses opportunities for pharmacists to reduce opioid prescription rates.

The report examines changing areas that will impact pharmacists.

Pharmacy teams from 6 institutes won the ASHP Best Practices Award.

ASHP’s 2016 Midyear Clinical Meeting is the largest gathering of clinical pharmacists in the world.

The holidays are just around the corner, but that’s not the only exciting thing about this time of year. ASHP’s 2016 Midyear Clinical Meeting is coming up, and Pharmacy Times is on site covering it.

Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic gives examples of certain off-label uses for NOACs that seem promising.

Patrick Dougherty, PharmD, BCPS,clinical pharmacist at the Emergency Medicine Peninsula Regional Medical Center, provides an overview of the various types of burns a patient can sustain.

Teresa Rubio, PharmD, of the FDA Office on Health and Constituents outlines why it is important for pharmacists to report to MedWatch.

James Hoffman, PharmD, MS, FASHP of St. Jude Children's Research Hospital, discusses some of the major trends in pharmacy. This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses what pharmacists should know about the duration of dual antiplatelet therapy.

The American Society of Health-System Pharmacists has just finished celebrating 50 years of its Midyear Clinical Meeting.

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of antiplatelet agent chosen can impact patient outcomes.

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses the importance of counseling patients with acute coronary syndrome.

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of stent used impacts the duration of dual antiplatelet therapy.

Do you know the current guidelines for using dual antiplatelet therapy after drug-eluting stent implantation?

Pharmacists should learn how to properly diagnose foreign-acquired diseases in order to optimize outcomes for infected patients.

Matthew C. Grissinger, RPh, FISMP, FASCP, director, of error reporting programs at the Institute for Safe Medication Practices, discusses medication use risk outside the pharmacy.

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses what the role of the pharmacist is in acute coronary syndrome management with platelet aggregation inhibitors.

Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses the role of platelet aggregation inhibitors in ACS management.

Identifying medication use risks outside the hospital pharmacy requires something simple: speaking with other members of the health care team.

Health-system pharmacists must look beyond immediate operational challenges and consider the larger trends that will ultimately affect their practices.

James Hoffman, PharmD, MS, FASHP of St. Jude Children's Research Hospital, describes how the growing trend of patient empowerment will affect the practice of pharmacy going forward.

Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses the different nuances pharmacists have to consider when using platelet aggregation inhibitors in different patient populations.

Patrick Dougherty, PharmD, BCPS, a clinical pharmacist at the Emergency Medicine Peninsula Regional Medical Center, talks about some memorable experiences he has had with burn patients.

Pharmacists should take advantage of the FDA's adverse drug event reporting system to promote patient safety.

Andrew North, PharmD, BCPS, a specialty practice pharmacist in emergency medicine at the Ohio State University Wexner Medical Center, discusses the pharmacist's role in acute coronary syndrome management with platelet aggregation inhibitors.